Intake of Omega-3 LCPUFAs EPA/DHA may contribute to prevent/manage NAFLD through several mechanisms involving induction of fatty acid oxidation and reduction of de novo lipogenesis (acting as endogenous ligands of peroxisome proliferator-activated receptor-α PPARα; which is also activated by fibrates), and simultaneous inhibition of the transcriptional regulators Carbohydrate Response-Element Binding protein (ChREBP) and Sterol Response Element Binding Protein 1c (SREBP1c) [98]. Here, MLXIPL is linked to metabolic dysfunction-associated steatotic liver disease.